Management of Borderline‑High Triglycerides (150–199 mg/dL) in Patients Already on Statin Therapy

Risk Assessment & Treatment Targets

Calculate non‑HDL‑C (total cholesterol − HDL‑C) as the secondary lipid target whenever triglycerides are ≥150 mg/dL. This step is essential for patients with a triglyceride level of 186 mg/dL, which falls into the borderline‑high category (150–199 mg/dL). 1
For patients with established ASCVD or very‑high cardiovascular risk:
- If non‑HDL‑C ≥ 130 mg/dL, intensify therapy with a higher‑dose statin or add niacin or fibrate (Class I). 1
- If non‑HDL‑C ≥ 100 mg/dL (very‑high‑risk subgroup), additional therapy is reasonable (Class IIa). 1
For primary‑prevention patients with triglycerides 150–199 mg/dL: therapeutic lifestyle changes are the primary recommendation; drug therapy is generally reserved for triglycerides ≥ 200 mg/dL (Class I). 6

Dietary modifications (Class I):
- Reduce saturated fat to < 7 % of total calories. 1
- Limit dietary cholesterol to < 200 mg per day. 1
- Reduce trans‑fatty acids to < 1 % of total calories. 1
- Limit alcohol intake to ≤ 2 drinks/day for men and ≤ 1 drink/day for women. 7
- Refer the patient to a registered dietitian nutritionist for individualized counseling. 8
Physical activity & weight management (Class I):
- Perform 30–60 minutes of moderate‑intensity aerobic exercise on at least 5 days per week (preferably daily). 1
- Aim for a body‑mass index of 18.5–24.9 kg/m². 1
- Initiate weight‑management strategies when waist circumference is ≥ 35 inches (women) or ≥ 40 inches (men). 9

When triglycerides remain 200–499 mg/dL after lifestyle optimization or non‑HDL‑C is above target:
- Intensify statin therapy to a higher dose (Class I). 1
- Add niacin (Class IIa) after achieving maximal LDL‑C lowering with statin. 4
- Add fibrate (Class IIa) after maximal LDL‑C lowering with statin. 4
Safety considerations: The combination of high‑dose statin plus fibrate markedly increases the risk of severe myopathy; therefore, when a fibrate is used, statin dose should be kept relatively low. 4
For triglycerides ≥ 500 mg/dL: initiate fibrate or niacin therapy before LDL‑C‑lowering therapy to reduce the risk of acute pancreatitis (Class I). 1

If triglycerides are ≥ 200 mg/dL, target non‑HDL‑C < 130 mg/dL (Class I). 1
For very‑high‑risk patients with triglycerides ≥ 200 mg/dL, a non‑HDL‑C goal of < 100 mg/dL is reasonable (Class IIa). 1

Reassess the lipid panel 4–12 weeks after any therapeutic change to determine whether non‑HDL‑C goals have been achieved. 1
If non‑HDL‑C remains above goal after 12 weeks of intensive lifestyle changes, consider higher‑dose statin and/or addition of niacin or fibrate (with caution regarding statin‑fibrate interaction). 6

In statin‑treated patients with acute coronary syndrome, on‑treatment triglyceride levels ≥ 150 mg/dL were independently associated with a higher risk of recurrent coronary events (hazard ratio 0.80; 95 % CI 0.66–0.97; p = 0.025). 8

All recommendations are derived from American Heart Association / American College of Cardiology guideline statements (Class I–IIa as indicated).